New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures

Table 1 Detailed characteristics of patients in the anti-reflux plastic stent group and traditional plastic stent group

	ARPS group	TPS group	P value
Patients, n	67	66	-
Sex, male/female	39/28	37/29	0.8023
Age, yr1	63.4 (16.6); [24-99]	65.4 (14.7); [31-93]	0.2254
Etiologies			0.3243
MBS	48	42
BBS	19	24
Preoperative liver function test results2
Total bilirubin, mmol/L	126.0 (196.9); [7.2-523.3]	156.1 (224.3); [6.8-536.5]	0.7875
Direct bilirubin, mmol/L	117.3 (163.5); [2.1-417.7]	136.1 (217.9); [2.3-456.3]	0.8225
Alkaline phosphatase, IU/L	401.0 (456.0); [75.0-2240.0]	408.0 (400.7); [77.0-1928.0]	0.3025
Glutamyl-transpeptidase, IU/L	558.0 (543.0); [25.0-2067.0]	421.0 (546.7); [19.0-2488.0]	0.0915
Cholecystectomy history	14 (20.9%)	22 (33.3%)	0.1063
Cholangitis prior to ERCP	8 (11.9%)	15 (22.7%)	0.1003
Cholelithiasis	11 (16.4%)	16 (24.2%)	0.2623
Duodenal parapapillary diverticulum	4 (6.0%)	4 (6.1%)	1.0006
Endoscopic sphincterotomy	42 (62.7%)	38 (57.6%)	0.5473
Stricture location, proximal/distal	12/55	11/55	0.8503
Stent length, cm2	7.0 (3.0); [5.0-12.0]	7.0 (4.0); [5.0-14.0]	0.6925

¹Mean (standard deviation) [range].

²Median (interquartile range) [range].

³Chi-squared test.

⁴Student’s t test.

⁵Mann-Whitney U test.

⁶Fisher’s exact test. ARPS: Anti-reflux plastic stent; TPS: Traditional plastic stent; ERCP: Endoscopic retrograde cholangiopancreatography; MBS: Malignant biliary stricture; BBS: Benign biliary stricture.